Sionna Therapeutics is expected to report zero revenue and a consensus EPS of -$0.62 for Q3 2026, with its current share price of $38.42 trading well below the average analyst price target of $62.14. The primary focus for investors this quarter is the clinical development progress of the company’s pipeline, specifically updates on Phase 2 trials for NBD1 stabilizers in cystic fibrosis.
Management is also expected to provide clarity on the company's cash runway and R&D spending as it advances its triple combination therapies. Following recent momentum in the biotechnology sector, market participants are looking for specific enrollment timelines for the SION-638 and SION-109 programs to gauge the competitive timeline against established CFTR modulators.